首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.
【24h】

Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.

机译:T淋巴细胞中G1周期阻滞的诱导导致细胞内β趋化因子水平升高:一种抑制R5 HIV-1的策略。

获取原文
获取原文并翻译 | 示例
           

摘要

The beta-chemokines RANTES (regulated on activation, normal T cell expressed and secreted), macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta are the natural ligands of the HIV-1 coreceptor CCR5 and compete with the virus for receptor binding. We show that secretion of the beta-chemokines by activated lymphocytes starts before cellular DNA synthesis is detected and demonstrate that transient prolongation of the G(1) phase of the cell cycle by treatment with cytostatic drugs results in increased levels of the three chemokines in culture supernatants. Supernatants collected from peripheral blood mononuclear cells exposed to hydroxyurea, which arrests the cell cycle in late G(1), contained high levels of beta-chemokines. These supernatants were able to inhibit HIV-1 replication when added to cultures of infected lymphocytes. The observed antiviral effect likely was due to the increased levels of beta-chemokines RANTES, MIP-1alpha, and MIP-1beta because (i) supernatants greatly inhibited the replication of HIV-1 BaL, whereas they affected HIV-1 IIIb replication only slightly; (ii) neutralizing antibodies against the chemokines abrogated the antiviral effect of the supernatants; and (iii) the hydroxyurea concentrations shown to up-regulate chemokine levels were not sufficient to inhibit virus replication by depletion of intracellular nucleotide pools. Although antiviral properties have been reported previously for the cytostatic agents shown here to up-regulate beta-chemokine levels, our results provide an additional mechanism by which these drugs may exert antiviral activity. In summary, increased extracellular levels of anti-HIV-1 beta-chemokines resulting from transient prolongation of the G(1) phase of the lymphocyte cell cycle by treatment with cytostatic drugs may help to control the replication of CCR5-using strains of HIV-1.
机译:β趋化因子RANTES(受激活,正常T细胞表达和分泌的调节),巨噬细胞炎性蛋白1alpha(MIP-1alpha)和MIP-1beta是HIV-1共受体CCR5的天然配体,并与病毒竞争受体结合。我们表明被激活的淋巴细胞的β趋化因子的分泌开始之前检测到细胞DNA合成,并表明通过细胞抑制药物治疗细胞周期G(1)期的短暂延长导致培养物中三种趋化因子水平的提高上清液。从暴露于羟基脲的外周血单核细胞收集的上清液,其在G(1)晚期停止了细胞周期,并含有高水平的β-趋化因子。当将这些上清液添加到感染的淋巴细胞培养物中时,它们能够抑制HIV-1复制。观察到的抗病毒作用可能是由于增加了β-趋化因子RANTES,MIP-1alpha和MIP-1beta的水平,因为(i)上清液极大地抑制了HIV-1 BaL的复制,而它们仅轻微影响了HIV-1 IIIb的复制; (ii)对抗趋化因子的中和抗体消除了上清液的抗病毒作用; (iii)显示出上调趋化因子水平的羟基脲浓度不足以通过消耗细胞内核苷酸库来抑制病毒复制。尽管以前已经报道了此处所示的细胞抑制剂可上调β趋化因子水平的抗病毒特性,但我们的结果提供了这些药物发挥抗病毒活性的另一机制。总之,通过用细胞抑制药物治疗,淋巴细胞细胞周期的G(1)期短暂延长而导致的抗HIV-1β趋化因子的细胞外水平升高,可能有助于控制使用CCR5的HIV-病毒株的复制1。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号